(This document
has been abbreviated unchanged from the original document
except for the bold emphasis editing by Stuart Thomson,
Director, the Gaia Research Institute. S.T.) (We are keen
to determine whether this research has been taken into
consideration by the Medicines Control Council in its
recent re-endorsement of this deadly toxic agent. S.T.)

3'-Azido-3'-deoxythymidine (AZT) is the
most widely used and evaluated chemotherapeutic agent
for the treatment of persons with acquired immune deficiency
syndrome (AIDS) and persons seropositive for human immunodeficiency
virus (HIV). The National Cancer Institute nominated
AZT for toxicity and carcinogenicity studies because of
the impending large-scale use of AZT in the treatment
of adult patients with AIDS or AIDS-related complex.

All groups of male and
female mice receiving AZT exhibited changes in peripheral
blood and bone marrow characteristic of a dose- and time-dependent,
minimal to mild, macrocytic, nonresponsive anemia. In
females, these changes were evident throughout the study.
In males, the macrocytic anemia had resolved by week 80
in the 30 mg/kg group; at study termination erythrocyte
macrocytosis was present only in males receiving 60 or
120 mg/kg AZT.

Pathology Findings

Incidences of squamous
cell carcinoma and squamous cell papilloma or carcinoma
(combined) of the vagina occurred with a positive trend
and were significantly increased in groups of female mice
receiving 60 or 120 mg/kg AZT. Epithelial hyperplasia
was observed in all dosed groups of females, and the incidence
was significantly increased in the 120 mg/kg AZT group.

Three renal tubule adenomas and
one renal tubule carcinoma were observed in male mice
receiving 120 mg/kg AZT; the combined incidence in this
group exceeded the range in historical controls. Evaluation
of step sections revealed a few more renal tubule hyperplasias.

The incidence of harderian gland
adenoma was increased in male mice receiving 120 mg/kg
AZT and exceeded the range in historical controls.

Under the conditions of
these 2-year gavage studies there was equivocal evidence
of carcinogenic activity of AZT in male mice based on
increased incidences of renal tubule and harderian gland
neoplasms in groups receiving AZT alone. There was clear
evidence of carcinogenic activity of AZT in female mice
based on increased incidences of squamous cell neoplasms
of the vagina in groups that received AZT.

Hematotoxicity occurred
in all groups that received AZT.

Treatment with AZT resulted
in increased incidences of epithelial hyperplasia of the
vagina in all dosed groups of females.

NB: To view the
Adobe Acrobat files, which can be downloaded from
pages on this site, you require an Adobe Acrobat
Reader. You may download this free software by simply
clicking on the button below.

(Editor’s Comment:
Preliminary data has for several years indicated that
AZT represented unacceptable risks. Responsible scientists
accordingly called for comprehensive testing such as that
reported above, which is always mandatory prior to the
approval of all other drugs before licensing. AZT (as
is Fluoride) is unique in that it alone was approved for
“human experimentation” prior to such animal
studies having been conducted, and this for the treatment
of a disease of widely scientifically disputed etiology.
Existing pro-AZT studies are fraudulent in that they have
been subject to serious methodological flaws and or were
strategically terminated prematurely, prior to the drug
revealing it’s true unacceptable risk / benefit
profile and the paradoxical inevitable suppression of
immunity, not similarly prevented by experimental termination
in real-life applications of this drug. For insight into
the fraudulent trials see: http://www.virusmyth.net/aids/data/jlfraud.htm
S.T.)

CONGRATULATIONS
you have reached the end of this page. Use either the back
button to return to the previous page or navigate further
using the links below